Vanguard Group Inc Fate Therapeutics Inc Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 8,766,764 shares of FATE stock, worth $8.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,766,764

Previous 10,310,453 14.97%

Holding current value

$8.42 Million

Previous $8.15 Million 20.54%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$0.68 - $1.67 $1.05 Million - $2.58 Million	-1,543,689 Reduced 14.97%	8,766,764 $9.82 Million
Q1 2025 May 09, 2025	SELL	$0.79 - $1.87 $17,838 - $42,224	-22,580 Reduced 0.22%	10,310,453 $8.15 Million
Q4 2024 Feb 11, 2025	SELL	$1.61 - $3.35 $114,454 - $238,151	-71,090 Reduced 0.68%	10,333,033 $17 Million
Q3 2024 Nov 13, 2024	SELL	$3.12 - $5.57 $516,955 - $922,898	-165,691 Reduced 1.57%	10,404,123 $36.4 Million
Q2 2024 Aug 13, 2024	BUY	$3.26 - $7.08 $2.15 Million - $4.66 Million	658,807 Added 6.65%	10,569,814 $34.7 Million
Q1 2024 May 10, 2024	BUY	$3.54 - $8.35 $2.19 Million - $5.16 Million	617,644 Added 6.65%	9,911,007 $72.7 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $2.66 Million - $6.36 Million	-1,614,988 Reduced 14.81%	9,293,363 $34.8 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $1.65 Million - $4.11 Million	-815,023 Reduced 6.95%	10,908,351 $23.1 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $3.63 Million - $5.02 Million	762,427 Added 6.96%	11,723,374 $55.8 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $12.7 Million - $33.2 Million	2,988,396 Added 37.48%	10,960,947 $62.5 Million
Q4 2022 Feb 10, 2023	BUY	$9.86 - $23.83 $1.55 Million - $3.75 Million	157,571 Added 2.02%	7,972,551 $80.4 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $1.2 Million - $2.06 Million	57,040 Added 0.74%	7,814,980 $175 Million
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $1.19 Million - $2.83 Million	66,768 Added 0.87%	7,757,940 $192 Million
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $456,472 - $927,407	15,385 Added 0.2%	7,691,172 $298 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $2.37 Million - $3.18 Million	49,441 Added 0.65%	7,675,787 $449 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $3.3 Million - $5.33 Million	55,665 Added 0.74%	7,626,346 $452 Million
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $509 Million - $700 Million	7,570,681 New	7,570,681 $657 Million

Others Institutions Holding FATE

# of Institutions

150

Shares Held

83.4M

Call Options Held

179K

Put Options Held

13.4K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $93.1M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Fate Therapeutics Inc Transaction History